miRNA therapeutics targeting RAS networks

High anti-tumor activity for wide range of RAS mutated cancers by chemically-modified miR-143#12 (Tumor-suppressor miRNA)


  •  Multiple-target suppression for RAS, KRAS signal network (AKT and ERK) and SOS1
  • Artificially modified nucleic acid optimized to increase RNase degradation resistance of miR-143
  • Anti-tumor activity at low concentration   ex.) DLD-1  IC50 : 1.32nM
  • Synergetic anti-tumor effect for KRAS mutated cancer by combination therapy with EGFR inhibitor, Cetuximab

Background and Technology

miR-143 is localized on chromosome 5q32, frequently under-expressed in variety of cancer and suggested involvement with cancer as tumor suppressor miRNA. miR-143 has been reported not only silencing total RAS, but also its downstream, effector signal molecules ERK and AKT and expressing synergetic suppressive effect.
Inventors found that miR-143#12 which was originally designed and modified based on the natural human miR-143 showed strong anti-tumor effect. As a background of high activity, it is suggested that miR-143#12 has excellent RNase resistant and remained long-term activity.
The effect of miR-143#12 in vitro has been proved and we demonstrated that human tumor cell line xenografted nude-mouse i.v. administrated miR-143#12 showed a remarkable anti-tumor effect at a low dose in all cases (Colon cancer, Bladder cancer, Gastric cancer, Kidney cancer, Rhabdomyosarcoma). For animal injection, miRNA‐143#12 was loaded in polyionic copolymers (PIC) to deliver miRNA to the tumors, but the delivery system is not limited to PIC.

Left: Sequences of synthetic miR-143 used in this study.
F RNA; Fluoro-RNA, Ome RNA; O-Methyl RNA, PS; phosphorothioate

Right: Remaining percentage of each miR‐143, Am, #1 and #12, remaining in the presence of FBS evaluated by performing RT‐qPCR. The 0‐min value of each miR‐143 is indicated as 100%. The mean value was taken for each time.


Effect of miRNA 143#12 single and c ombination with Cetuximab (Erbitux)


JP6730717, US16/092,830, EP3444345, CN109477090A


Cancers 2020, 12(11), 3312.
Colon cancer
Cancer Sci. 2018 May;109(5):1455-1467.
Bladder cancer
Mol Ther Methods Clin Dev. 2019 Feb 20;13:290-302.
Gastric cancer
J Mol Sci. 2019 Apr 5;20(7):1697.
https://doi: 10.3390/ijms20071697
Kidney cancer
Mol Ther. 2019 May 8;27(5):1017-1027.


W e are looking for pharmaceutical or biotech companies who are interested in d evelopment new miRNA t herapeutics by using miR 143#12. We are happy to license or to provide miR-143#12 as a material sample for validation or obtaining data.
We would appreciate it if you could let us know your feedback.

Product No. ON-03809

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name


Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.